Lavie Bio, a subsidiary of Evogene (EVGN), announced that it is extending its joint validation trials for its biofungicides conducted by Bayer (BAYRY), after successful first-year laboratory and greenhouse testing. The tests have demonstrated the efficacy of Lavie Bio’s biofungicides in addressing devastating diseases that affect fruits and vegetables worldwide. Building on these positive outcomes, the companies are progressing to a second year of validation trials in field experiments.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAYRY:
- Crispr Therapeutics proposes to elect Christian Rommel to board of directors
- Bayer says ‘structural change is not the current optimal course of action’
- Bayer price target lowered to EUR 28 from EUR 30 at Barclays
- Bayer price target lowered to EUR 29 from EUR 34 at Deutsche Bank
- Bayer downgraded to Market Perform from Outperform at Bernstein
